Superiority of MLR Over NLR and PLR In Predicting Advanced Stage Disease In Treatment-Naive Serous Ovarian Cancer
Journal of Basic and Clinical Health Sciences · 31.05.2026 · 10 (2) · 276-285
DOI: 10.30621/jbachs.1918061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Basic and Clinical Health Sciences, online erschienen am 31.05.2026. Verfasst von Orkun İlgen und 5 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Gefördert von: None..
Abstract (Originalsprache)
Purpose
The prognostic value of systemic inflammatory markers in ovarian cancer is contradictory. This study aimed to compare the performance of monocyte-lymphocyte ratio (MLR) in predicting advanced stage disease and peritoneal metastasis with neutrophil-lymphocyte (NLR) and platelet-lymphocyte ratio (PLR) in treatment-naive serous ovarian cancer.Material and methods: NLR, PLR, and MLR were calculated from preoperative blood samples of 63 treatment-naive ovarian cancer patients (58 serous, 92.1%) who underwent primary debulking surgery. FIGO 2021 staging criteria were used. Mann-Whitney U and Kruskal-Wallis tests (with Bonferroni correction) were used for intergroup comparisons; multivariate logistic regression analysis was applied to determine independent predictors. The discriminative performance of MLR was evaluated using ROC analysis.
Results
92.1% of the cohort had serous histology, and 61.9% had advanced-stage disease (FIGO stages III-IV). In multivariate analysis (adjusted for age and menopause), only MLR was found to be independently associated with advanced-stage disease (adjusted OR: 4.25; 95% CI: 1.24-14.49; p=0.021). NLR and PLR showed no significance. MLR was also associated with peritoneal metastasis (p=0.017) and intestinal infiltration (p=0.019). In ROC analysis, the AUC was 0.706 (95% CI: 0.567-0.845; p=0.006). The optimal cut-off value was determined as 0.30 (sensitivity 48.7%, specificity 91.7%); an alternative cut-off value of 0.17 (sensitivity 82.1%, specificity 50.0%) was evaluated for high sensitivity.
Conclusion
In treatment-naive serous ovarian cancer, MLR demonstrated superior performance compared to NLR and PLR in predicting advanced disease and peritoneal metastasis (adjusted OR: 4.25; AUC: 0.706). This finding supports the clinical significance of the monocyte-macrophage axis in serous ovarian cancer with predominantly transcoelomic spread. The prognostic value and optimal cut-off values of MLR should be confirmed by prospective multicenter studies.
Förderung
- None.
Zitieren
APA
İlgen, O., Yozgat, S. T., Aras, G., Tekgündüz, S. E., Çelebioğlu, N. O., & Kadıoğlu, B. G. (2026). Superiority of MLR Over NLR and PLR In Predicting Advanced Stage Disease In Treatment-Naive Serous Ovarian Cancer. Journal of Basic and Clinical Health Sciences, 10(2), 276-285. https://doi.org/10.30621/jbachs.1918061
Vancouver
İlgen O, Yozgat ST, Aras G, Tekgündüz SE, Çelebioğlu NO, Kadıoğlu BG. Superiority of MLR Over NLR and PLR In Predicting Advanced Stage Disease In Treatment-Naive Serous Ovarian Cancer. Journal of Basic and Clinical Health Sciences. 2026;10(2):276-285. doi:10.30621/jbachs.1918061
BibTeX
@article{lgen2026,
author = {İlgen, Orkun and Yozgat, Simge Tezel and Aras, Gokhan and Tekgündüz, Sibel Ejder and Çelebioğlu, Nazım Ozan and Kadıoğlu, Berrin Göktuğ},
title = {Superiority of MLR Over NLR and PLR In Predicting Advanced Stage Disease In Treatment-Naive Serous Ovarian Cancer},
journal = {Journal of Basic and Clinical Health Sciences},
year = {2026},
volume = {10},
number = {2},
pages = {276--285},
doi = {10.30621/jbachs.1918061}
}
EUVIMED